849094-03-7 Usage
Uses
Used in Pharmaceutical Industry:
2-(chloroMethyl)-6-(trifluoroMethyl)pyridine is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
2-(chloroMethyl)-6-(trifluoroMethyl)pyridine is employed as an intermediate in the production of pesticides, herbicides, and fungicides. Its presence in these agrochemicals helps enhance their effectiveness in controlling pests and diseases in agriculture.
Used in Advanced Materials and Fine Chemicals:
2-(chloroMethyl)-6-(trifluoroMethyl)pyridine serves as a building block in the creation of advanced materials and fine chemicals. Its unique properties contribute to the development of innovative products with diverse applications.
Due to its potential applications in both pharmaceutical and agricultural industries, 2-(chloroMethyl)-6-(trifluoroMethyl)pyridine is of significant interest to researchers and chemical manufacturers, driving further exploration and development in these fields.
Check Digit Verification of cas no
The CAS Registry Mumber 849094-03-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,9,0,9 and 4 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 849094-03:
(8*8)+(7*4)+(6*9)+(5*0)+(4*9)+(3*4)+(2*0)+(1*3)=197
197 % 10 = 7
So 849094-03-7 is a valid CAS Registry Number.
849094-03-7Relevant articles and documents
PROCESSES AND INTERMEDIATES FOR PREPARING CYSTEINE PROTEASE INHIBITORS
-
Page/Page column 71, (2010/10/20)
The present invention is directed to a novel process for preparing certain cysteine protease inhibitors.
HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
-
Page/Page column 81, (2008/06/13)
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.